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Abstract—Carbon-11-labeled serotonin (5-hydroxytryptamine) 6 receptor (5-HT6R) antagonists, 1-[(2-bromophenyl)sulfonyl]-5-
[11C]methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole (O-[11C]2a) and 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-
[11C]methyl-1-piperazinyl)methyl]-1H-indole (N-[11C]2a), 5-[11C]methoxy-3-((4-methylpiperazin-1-yl)methyl)-1-(phenylsulfonyl)-1H-
indole (O-[11C]2b) and 5-methoxy-3-((4-[11C]methylpiperazin-1-yl)methyl)-1-(phenylsulfonyl)-1H-indole (N-[11C]2b), 1-((4-
isopropylphenyl)sulfonyl)-5-[11C]methoxy-3-((4-methylpiperazin-1-yl)methyl)-1H-indole (O-[11C]2c) and 1-((4-
isopropylphenyl)sulfonyl)-5-methoxy-3-((4-[11C]methylpiperazin-1-yl)methyl)-1H-indole (N-[11C]2c), 1-((4-fluorophenyl)sulfonyl)-5-
[11C]methoxy-3-((4-methylpiperazin-1-yl)methyl)-1H-indole (O-[11C]2d) and 1-((4-fluorophenyl)sulfonyl)-5-methoxy-3-((4-
[11C]methylpiperazin-1-yl)methyl)-1H-indole (N-[11C]2d), were prepared from their O- or N-desmethylated precursors with [11C]CH3OTf
through O- or N-[11C]methylation and isolated by HPLC combined with SPE in 40-50% radiochemical yield, based on [11C]CO2 and
decay corrected to end of bombardment (EOB). The radiochemical purity was >99%, and the molar activity (MA) at EOB was 370-740 
GBq/µmol with a total synthesis time of ~40-minutes from EOB.  
Keywords: Serotonin (5-hydroxytryptamine) 6 receptor (5-HT6R); Carbon-11-labeled 5-HT6R antagonists; Radiosynthesis;
Positron emission tomography (PET); Alzheimer’s disease (AD). 
Alzheimer’s disease (AD) is the most common form of 
dementia and affects close to 50 million people 
worldwide in 2017.1 The disease is divided into four 
stages, including predementia, early dementia, moderate 
AD and advanced AD.2 The cause for most AD cases is 
still unknown, and there are several competing 
hypotheses like genetic, cholinergic hypothesis, amyloid 
hypothesis, and tau hypothesis, trying to explain it.3 AD 
might be treated by symptomatic treatments and 
disease-modifying therapies such as neuroprotective and 
neurorestorative therapies, however, none effective 
strategy is approved for preventing, curing and slowing 
the progress of AD.4 The current available medications 
can only be used to treat the cognitive problems of AD, 
focused on acetylcholinesterase inhibitors (AChEIs) 
including tacrine, rivastigmine, galantamine, and 
donepezil, as well as a N-methyl-D-aspartate (NMDA) 
receptor antagonist memantine.5 The benefit from these 
approved cognitive enhancing drugs for AD is small, 
and novel alternate therapy for treating cognitive 
disorders is eagerly needed.6 Since the clinical trial of 
the disease-modifying therapies in AD is an extremely 
complex process with very high failure rate, the 
researchers have turned their focus to symptomatic 
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treatment, and serotonin (5-hydroxytryptamine) 6 
receptor (5-HT6R) has become a promising alternative 
target.7 5-HT6R is a subtype of 5-HT receptor, and it is a 
G protein-coupled receptor (GPCR). 5-HT6R 
antagonists have been hypothesized to improve 
cognition, learning, and memory.8 
 
To discover more effective treatments, reliable 
diagnostic tools are really needed. Neuroimaging of AD 
becomes one of the most active as well as most 
challenging areas in neuroscience.9 Advanced 
biomedical imaging technique positron emission 
tomography (PET) is a promising modality for AD, and 
significant advances have occurred in this field of 
molecular imaging.10 The development of PET imaging 
probes for in vivo detection of Alzheimer’s brains is 
critical for early and accurate diagnosis and for the 
successful discovery of AD therapies.11 Previous PET 
AD imaging agent development is based on cholinergic 
hypothesis, amyloid hypothesis, and tau hypothesis. The 
representative PET tracers in clinical evaluations such 
as carbon-11-labeled AChEIs [11C]AMP ([11C]MP4A),  
[11C]PMP ([11C]MP4P), and [11C]Donepezil;12-14 β-
amyloid plaques (Aβ) tracers [11C]PIB and [18F]Amyvid 
([18F]AV-45);15,16 and tau tracers [11C]PBB3 and 
[18F]T807 ([18F]AV-1451)17,18 are listed in Figure 1. 
The success and limitations of Aβ imaging and tau 
imaging have spurred efforts worldwide to develop new 
selective PET tracers for different imaging targets. Our 
efforts toward the development of PET agents for AD 
diagnosis have been ongoing quite some time, and a 
series of enzyme- or receptor-based PET agents have 
been developed in this laboratory. In our previous work, 
we have targeted the enzyme glycogen synthase kinase-
3 (GSK-3) and developed carbon-11-labeled GSK-3 
inhibitors19,20 as PET AD imaging agents (Figure 1). In 
this ongoing study, we target 5-HT6R, which is a novel 
and attractive molecular target for treatment and PET 
imaging of AD.8 Several 5-HT6R PET tracers such as 
[18F]12ST05, [11C]GSK215083 and [11C]SB399885, as 
shown in Figure 2, have been previously developed, 
however, preclinical and clinical evaluation indicated 
these radioligands have significant drawbacks like no 
specific binding, high non-specific binding, poor brain 
entry and inconsistent brain uptake compared to known 
5-HT6R distribution.21-23 Thus an ideal 5-HT6R 
radioligand that can be used in the clinical setting to 
study 5-HT6R expression levels in AD remains to be 
discovered. Recently a novel series of 3-
(piperazinylmethyl) indole derivatives have been 
developed as 5-HT6R antagonists for potential treatment 
of AD, and the representative compounds, 1-[(2-
bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-
piperazinyl)methyl]-1H-indole (2a), 5-methoxy-3-((4-
methylpiperazin-1-yl)methyl)-1-(phenylsulfonyl)-1H-
indole (2b), 1-((4-isopropylphenyl)sulfonyl)-5-
methoxy-3-((4-methylpiperazin-1-yl)methyl)-1H-indole 
(2c) and 1-((4-fluorophenyl)sulfonyl)-5-methoxy-3-((4-
methylpiperazin-1-yl)methyl)-1H-indole (2d), exhibited 
high binding affinity to human 5-HT6R with Ki value 
2.0, 4.3, 1.6 and 5.0 nM, respectively, and high 
selectivity over 100 target sites.24 These compounds 
possesses the combination of favorable binding affinity 
and selectivity to 5-HT6R, and O- and N-methyl 
positions amenable to labeling with carbon-11, 
therefore, their carbon-11-labeled radioligands are 
expected to have high specific binding. Here, we report 
the synthesis of carbon-11-labeled 5-HT6R antagonists 
labeled at oxygen or nitrogen positions O-[11C]2a-d and 
N-[11C]2a-d (Figure 2) as new potential PET 
radioligands for imaging of AD. 
  
 
Figure 1. PET radiotracers for imaging of AD. 
 
 
Figure 2. 5-HT6R PET radioligands. 
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Scheme 1. Synthesis of reference standards 2a-d and O-desmethylated 
precursors 3a-d. 
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Scheme 2. Synthesis of N-desmethylated precursors 6a-d. 
 
The reference standards 2 (2a: R = 2-Br; 2b: R = H; 2c: 
R = 4-iPr; 2d: R = 4-F), their O-desmethylated 
precursors 3 (3a: R = 2-Br; 3b: R = H; 3c: R = 4-iPr; 
3d: R = 4-F) and N-desmethylated precursors 6 (6a: R = 
2-Br; 6b: R = H; 6c: R = 4-iPr; 6d: R = 4-F) were 
synthesized as depicted in Scheme 1 and Scheme 2 
according to the reported procedure with 
modifications.24-29 The main modifications included the 
use of different reagents, reactions and methods to 
synthesize new compounds O- and N-desmethylated 
precursors. 5-Methoxy-3-((4-methylpiperazin-1-yl) 
methyl)-1H-indole (1) and tert-butyl 4-((5-methoxy-1H-
indol-3-yl)methyl)piperazine-1-carboxylate (4) were 
achieved by well-known Mannich reaction from 
commercially available 5-methoxy-1H-indole and 1-
methylpiperazine or tert-butyl piperazine-1-carboxylate 
in 92% and 91% yield, respectively. Reference 
standards 2 (2a: R = 2-Br; 2b: R = H; 2c: R = 4-iPr; 2d: 
R = 4-F) was prepared from commercially procured aryl 
sulfonyl or substituted aryl sulfonyl by condensation 
with compound 1 in the presence of ground KOH in 
THF with 76-94% yield. Compounds 2 (2a: R = 2-Br; 
2b: R = H; 2c: R = 4-iPr; 2d: R = 4-F) were treated with 
48% HBr to provide the corresponding O-
desmethylated precursors 3 (3a: R = 2-Br; 3b: R = H; 
3c: R = 4-iPr; 3d: R = 4-F) in 88-94% yield. 
Compounds 5 (5a: R = 2-Br; 5b: R = H; 5c: R = 4-iPr; 
5d: R = 4-F) were prepared from commercially 
procured aryl sulfonyl or substituted aryl sulfonyl by 
condensation with compound 4 in the presence of 
ground KOH in THF with 90-96% yield. The 
deprotecting reaction of compounds 5 (5a: R = 2-Br; 
5b: R = H; 5c: R = 4-iPr; 5d: R = 4-F) with 
trifluoroacetic acid (TFA) in THF gave N-
desmethylated precursors 6 (6a: R = 2-Br; 6b: R = H; 
6c: R = 4-iPr; 6d: R = 4-F) in 91-96% yield.  
 
 
Scheme 3. Synthesis of target tracers (O-[11C]2a-d) labeled at oxygen 
position. 
 
 
Scheme 4. Synthesis of target tracers (N-[11C]2a-d) labeled at nitrogen 
position. 
 
Synthesis of the target tracer (O-[11C]2a-d and N-
[11C]2a-d) labeled at oxygen or nitrogen positions is 
shown in Scheme 3 and Scheme 4. O-Desmethylated 
precursors 3a-d and N-desmethylated precursors 6a-d 
underwent O- or N-[11C]methylation30,31 using the 
reactive [11C]methylating agent [11C]methyl triflate 
([11C]CH3OTf)32,33 in acetonitrile at 80 °C under basic 
conditions (2 M KOH). The product was isolated by 
semi-preparative reverse-phase (RP) high performance 
liquid chromatography (HPLC) with a C-18 column, 
and then concentrated by solid-phase extraction 
(SPE)34,35 with a disposable C-18 Light Sep-Pak 
cartridge to produce the corresponding pure 
radiolabeled compound O-[11C]2a-d or N-[11C]2a-d in 
40-50%  radiochemical yield, decay corrected to end of 
bombardment (EOB), based on [11C]CO2. 
 
The radiosynthesis includes three stages: 1) labeling 
reaction; 2) purification; and 3) formulation. We 
employed more reactive [11C]CH3OTf, instead of 
commonly used [11C]methyl iodide ([11C]CH3I),36 in O- 
or N-[11C]methylation to improve radiochemical yield 
of O-[11C]2a-d or N-[11C]2a-d from 30-40% to 40-50%. 
We used an Eckert & Ziegler Modular Lab C-11 Methyl 
Iodide/Triflate module to produce [11C]methylating 
agent either [11C]CH3OTf or [11C]CH3I ([11C]CH3Br 
passed through a NaI column). The direct comparison 
  
 
between [11C]CH3OTf and [11C]CH3I confirmed the 
result. The labeling reaction was conducted using a V-
vial method. Addition of aqueous NaHCO3 to quench 
the radiolabeling reaction and to dilute the radiolabeling 
mixture prior to the injection onto the semi-preparative 
HPLC column for purification gave better separation of 
O-[11C]2a-d or N-[11C]2a-d from its O-desmethylated 
precursors 3a-d or N-desmethylated precursors 6a-d. 
We used Sep-Pak trap/release method instead of 
rotatory evaporation for formulation to improve the 
chemical purity of radiolabeled products O-[11C]2a-d or 
N-[11C]2a-d. In addition, a C18 Light Sep-Pak to 
replace a C18 Plus Sep-Pak allowed final product 
formulation with ≤5% ethanol.37 Overall, it took ~40 
min for synthesis, purification and dose formulation.   
 
The radiosynthesis was performed in a home-built 
automated multi-purpose [11C]-radiosynthesis 
module.38-40 This radiosynthesis module facilitated the 
overall design of the reaction, purification and 
reformulation capabilities in a fashion suitable for 
adaptation to preparation of human doses. In addition, 
the module is designed to allow in-process measurement 
of [11C]-tracer molar activity (MA, GBq/µmol at EOB) 
using a radiation detector with a UV detector at the 
outlet of the HPLC-portion of the system. In the HPLC 
chromatogram, peak analysis of the chromatographic 
data utilized PeakSimple software (SRI Instruments, 
Las Vegas, NV).  Immediately following elution of the 
product peak, the chromatographic data are exported to 
PeakSimple readable files, and the area of the 
radioactivity peak is converted to GBq - mCi at EOB by 
comparison to a reference calibration curve previously 
constructed using the same detector, loop column, 
mobile phase and flow rate.  The mass peak from the 
UV chromatogram (without decay correction) is 
similarly compared to a standard curve made at the 
same UV wavelength, mobile phase and flow rate. 
Simple division of the total EOB radioactivity peak (in 
GBq - mCi) by the total mass peak (in nmoles) gives 
specific activity at EOB in GBq - Ci/µmol. For the 
reported syntheses, product MA was in a range of 370-
740 GBq/µmol at EOB. The factors that affect the EOB 
MA significantly to lead to such a wide range have been 
discussed in our previous works.41 The general methods 
to increase SA have been described as well, and the SA 
of our [11C]-tracers is significantly improved.41 The 
‘wide range’ of MA we reported is for the same [11C]-
tracer produced in different days, because very different 
[11C]-target and [11C]-radiosynthesis unit situations 
would make MA in a wide range. For a [11C]-tracer 
produced in the same day, the MA of the same tracer in 
different production runs will be in a small range, 
because [11C]-target and [11C]-radiosynthesis unit would 
not be much different in the same day. Likewise, the 
methods to minimize such wide range of MA from 
practice perspective have been provided in our previous 
works.42 At the end of synthesis (EOS), the MA of 
[11C]-tracer was determined again by analytical RP 
HPLC, calculated, decay corrected to EOB, and based 
on [11C]CO2, which was in agreement with the ‘on line’ 
determined value. In this work, semi-preparative HPLC 
was used for purification, thus the MA of [11C]-tracer 
was assessed by both semi-preparative HPLC (during 
synthesis) and analytical HPLC (EOS). 
 
Chemical purity and radiochemical purity were 
determined by analytical HPLC.43 The chemical purity 
of the precursor and reference standard was >95%. The 
radiochemical purity of the target tracer was >99% 
determined by radio-HPLC through γ-ray (PIN diode) 
flow detector, and the chemical purity of the target 
tracer was >95% determined by reversed-phase HPLC 
through UV flow detector. 
   
The octanol-water partition coefficient (commonly 
expressed as Log P) is an important physical parameter 
directly correlated with the biological activities of a 
wide variety of organic compounds.42 Log P provides an 
assessment of lipophilicity that often correlates with a 
compound’s ability to penetrate the blood brain barrier 
(BBB). We obtained Log P and calculated Log P (CLog 
P) values of carbon-11-labeled 5-HT6R antagonists O-
[11C]2a-d and N-[11C]2a-d (Figure 2) in comparison 
with [11C]PIB, [18F]Amyvid, [11C]PBB3 and [18F]T807 
(Figure 1) from ChemDraw Professional 15.1 
(ChemOffice) as listed in Table 1. Log P data of O-
[11C]2a-d and N-[11C]2a-d (2.59 - 3.83) are similar to 
those of [11C]PIB, [18F]Amyvid, [11C]PBB3 and 
[18F]T807 (2.25 – 4.09), which are PET AD imaging 
agents in clinical evaluation. These data suggest the O-
[11C]2a-d and N-[11C]2a-d have appropriate 
lipophilicity for brain uptake.   
 
Table 1. Log P and CLog P values of carbon-11-labeled 
5-HT6R antagonists 2a-d in comparison with [11C]PIB, 
[18F]Amyvid, [11C]PBB3 and [18F]T807. 
Compound Log P CLog P 
O- or N-[11C]2a 3.42 4.92 
O- or N-[11C]2b 2.59 4.05 
O- or N-[11C]2c 3.83 5.48 
O- or N-[11C]2d 2.75 4.20 
[11C]PIB 3.41 3.99 
[18F]Amyvid 3.16 3.91 
[11C]PBB3 4.09 4.05 
[18F]T807 2.25 3.18 
 
The stability of the labeled tracers O-[11C]2a-d and N-
[11C]2a-d was evaluated by analytical HPLC from EOS 
up to 3 h, one injection of the tracer solution in 
EtOH/saline onto HPLC column per hour. The HPLC 
  
 
chromatograms showed O-[11C]2a-d and N-[11C]2a-d 
were stable without decomposition.    
 
The experimental details and characterization data for 
compounds 1-6 and for the tracers O-[11C]2a-d and N-
[11C]2a-d are given.44 
 
In summary, synthetic routes with moderate to high 
yields have been developed to produce the reference 
standard 2a-d, O-desmethylated precursor 3a-d, N-
desmethylated precursor 6a-d, and target tracer O-
[11C]2a-d and N-[11C]2a-d. The radiosynthesis 
employed [11C]CH3OTf for O- or N-[11C]methylation at 
O- or N-position of 3-(piperazinylmethyl) indole 
desmethylated precursor, followed by product 
purification and isolation using a semi-preparative RP 
HPLC combined with SPE. O-[11C]2a-d and N-[11C]2a-
d were obtained in high radiochemical yield, 
radiochemical purity and chemical purity, with a 
reasonable short overall synthesis time, and high molar 
activity. This will facilitate studies to evaluate carbon-
11-labeled 5-HT6R antagonists O-[11C]2a-d and N-
[11C]2a-d as new candidate PET radioligands for 
imaging of AD.    
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44. (a). General: All commercial reagents and solvents 
were purchased from Sigma-Aldrich and Fisher 
Scientific, and used without further purification. 
[11C]CH3OTf was prepared according to a literature 
procedure.33 Melting points were determined on WRR 
apparatus and were uncorrected. 1H NMR spectra 
were recorded on a Bruker Avance II 600 MHz NMR 
Fourier transform spectrometer. Chemical shifts (δ) 
are reported in parts per million (ppm) relative to an 
internal standard tetramethylsilane (TMS, δ 0.0), and 
coupling constants (J) are reported in hertz (Hz). 
Liquid chromatography-mass spectra (LC-MS) 
analysis was performed on AB Sciex 4000Q Trap 
instrument, consisting of an 1100 series HPLC 
connected to a diode array detector and a 1946D mass 
spectrometer configured for positive-ion/negative-ion 
electrospray ionization (ESI). The high resolution 
mass spectra (HRMS) were obtained using a 
Waters/Micromass LCT Classic spectrometer. 
Chromatographic solvent proportions are indicated as 
volume: volume ratio. Thin-layer chromatography 
(TLC) was run using HS silica gel GF254 uniplates (5 
× 10 cm2).  Plates were visualized under UV light. 
Normal phase flash column chromatography was 
carried out on Combiflash Rf 150 silica gel 60 (300-
400 mesh) with a forced flow of the indicated solvent 
system in the proportions described below. All 
moisture- and air-sensitive reactions were performed 
under a positive pressure of nitrogen maintained by a 
direct line from a nitrogen source. Analytical RP 
HPLC was performed using a Prodigy (Phenomenex) 
5 µm C-18 column, 4.6 × 250 mm, a gradient mobile 
phase (40-80%) CH3CN/3 mM HCOONH4, flow rate 
1.6 mL/min; UV (254 nm) and γ-ray (PIN diode) flow 
detectors. Semi-preparative RP HPLC column was 
performed using a Prodigy (Phenomenex) 5 µm C-18 
column, 10 × 250 mm; 57% CH3CN:43% 0.1 M 
NaHCO3 mobile phase; 5, 4, 7, and 5 mL/min flow 
rate for O-[11C]2a and N-[11C]2a, O-[11C]2b and N-
[11C]2b, O-[11C]2c and N-[11C]2c, O-[11C]2d and N-
[11C]2d, respectively; UV (254 nm) and γ-ray (PIN 
diode) flow detectors. C18 Light Sep-Pak cartridges 
were obtained from Waters Corporation (Milford, 
MA).  Sterile Millex-FG 0.2 µm filter units were 
obtained from Millipore Corporation (Bedford, MA). 
(b). 5-Methoxy-3-[(4-methyl-1-piperazinyl)methyl]-
1H-indole (1): The formaldehyde solution (20 mL, 
30% w/v, 0.2 mol) was added to the stirred mixture of 
1-methylpiperazine (15.0 g, 0.15 mol) and acetic acid 
(6.0 g, 0.1 mol) in water (20 mL) at 10 ºC. The 
reaction mixture was stirred at 10 ºC for 15 min, it was 
warmed to room temperature (RT) and stirred for 
another 2 h. After the thick syrup was formed, it was 
added slowly to a stirred solution of 5-methoxy-1H-
indole (20 g, 0.13 mol) in MeOH (125 mL) at 5 ºC. 
The reaction mixture was warmed and stirred at RT 
for another 3 h. The mixture was poured into ice 
water, the pH was adjusted to 10-12 with aqueous 5 N 
NaOH solution, and extracted with EtOAc. The 
combined organic layer was washed with water, brine, 
dried over anhydrous Na2SO4 and filtered. The solvent 
was evaporated under vacuum. The crude product was 
purified by silica gel column chromatography with 
CH2Cl2/MeOH (100:1 to 10:1) as eluent to afford 1 as 
a white solid (32.5 g, 92%), mp 79.5-80.4 ºC. 1H 
NMR (600 MHz, CDCl3): δ 9.55 (s, 1H), 7.15 (d, J = 
2.4 Hz, 1H), 7.13 (d, J = 8.8 Hz, 1H), 6.95 (d, J = 1.9 
Hz, 1H), 6.81 (dd, J = 2.4, 8.8 Hz, 1H), 3.86 (s, 3H), 
3.71 (s, 2H), 2.48 (s, 8H), 2.30 (s, 3H). LC-MS (ESI, 
m/z): Calcd for C15H22N3O ([M+H]+) 260.2, found: 
260.2. 
(c). 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-
methyl-1-piperazinyl)methyl]-1H-indole (2a): To a 
stirred mixture of finely ground KOH solid (0.93 g, 
16.6 mmol) and 1 (2.0 g, 7.7 mmol) in THF (8.0 mL), 
2-bromobenzenesulphonyl chloride (2.6 g, 10.0 mmol) 
in THF (5.0 mL) was added at 15 ºC. After the 
reaction mixture was stirred at RT for 3 h, the mixture 
was poured into ice water and the pH was adjusted to 
9.5-10 with aqueous 2 N KOH solution. The mixture 
was extracted with EtOAc. The combined organic 
layer was washed with water, brine, dried over 
anhydrous Na2SO4 and filtered. The solvent was 
evaporated under vacuum. The crude product was 
purified by silica gel column chromatography with 
CH2Cl2/MeOH (200:1 to 20:1) as eluent to afford 2a 
as a white solid (3.3 g, 90%), mp 127.7-128.8 ºC. 1H 
NMR (600 MHz, CDCl3): δ 8.04 (dd, J = 1.5, 8.0 Hz, 
1H), 7.64 (t, J = 5.7 Hz, 2H), 7.54 (d, J = 9.0 Hz, 1H), 
  
 
7.43 (t, J = 7.6 Hz, 1H), 7.36 (dd, J = 1.5, 7.6 Hz, 1H), 
7.19 (d, J = 2.4 Hz, 1H), 6.84 (dd, J = 2.4, 8.9 Hz, 
1H), 3.62 (s, 2H), 3.83 (s, 3H), 2.32-2.50 (br, 8H), 
2.29 (s, 3H). LC-MS (ESI, m/z): Calcd for 
C21H25BrN3O3S ([M+H]+) 479.4, found: 479.9. 
Compounds 2b, 2c, and 2d were prepared with the 
same procedure according to 2a, and the data were 
listed as below. 5-Methoxy-3-((4-methylpiperazin-1-
yl)methyl)-1-(phenylsulfonyl)-1H-indole (2b): White 
solid (2.8 g, 90%), mp 125.1-125.4 ºC. 1H NMR (600 
MHz, CDCl3): δ 7.87 (d, J = 9.0 Hz, 1H), 7.81 (d, J = 
7.6 Hz, 2H), 7.44 (t, J = 7.4 Hz, 2H), 7.35 (t, J = 7.6 
Hz, 2H), 7.14 (d, J = 2.0 Hz, 1H), 6.91 (dd, J = 2.0, 
9.0 Hz, 1H), 3.79 (s, 3H), 3.55 (s, 2H,), 2.45 (br, 8H), 
2.26 (s, 3H). LC-MS (ESI, m/z): Calcd for 
C21H26N3O3S ([M+H]+) 400.2, found: 400.0. 1-((4-
Isopropylphenyl)sulfonyl)-5-methoxy-3-((4-
methylpiperazin-1-yl)methyl)-1H-indole (2c): White 
solid (2.6 g, 76%), mp 126.6-128.8 ºC. 1H NMR (600 
MHz, CDCl3): δ 7.88 (d, J = 9.0 Hz, 1H), 7.74 (d, J = 
8.4 Hz, 2H), 7.44 (s, 1H), 7.21 (d, J = 8.4 Hz, 2H), 
7.16 (d, J = 2.1 Hz, 1H), 6.92 (dd, J = 2.1, 9.0 Hz, 
1H), 3.79 (s, 3H), 3.57 (s, 2H), 2.86-2.81 (m, 1H), 
2.46 (br, 8H), 2.26 (s, 3H), 1.13 (d, J = 7.0 Hz, 6H). 
LC-MS (ESI, m/z): Calcd for C24H32N3O3S ([M+H]+) 
442.2, found: 442.0. 1-((4-Fluorophenyl)sulfonyl)-5-
methoxy-3-((4-methylpiperazin-1-yl)methyl)-1H-
indole (2d): White solid (3.0 g, 94%), mp 130.6-134.0 
ºC. 1H NMR (600 MHz, CDCl3): δ 7.85 (t, J = 8.8 Hz, 
3H), 7.40 (s, 1H), 7.11 (d, J = 2.0 Hz, 1H), 7.08 (t, J = 
8.5 Hz, 2H), 6.93 (dd, J = 2.0, 9.0 Hz, 1H), 3.83 (s, 
3H), 3.60 (s, 2H), 2.59 (br, 8H), 2.42 (s, 3H). LC-MS 
(ESI, m/z): Calcd for C21H25FN3O3S ([M+H]+) 418.2, 
found: 417.9. 
(d). 1-((2-Bromophenyl)sulfonyl)-3-((4-
methylpiperazin-1-yl)methyl)-1H-indol-5-ol (3a): To a 
solution of HBr (7 mL, 48% wt), 2a (2.0 g, 4.8 mmol) 
was added at RT under stirring, the resulting mixture 
was heated to 80 ºC and reaction continued for 12 h. 
The reaction mixture was poured into water (40 mL) 
after cooled to 25 ºC, and then extracted with CHCl3 
(3 × 40 mL) after the pH was adjusted to 10 with 
ammonia solution (17%). The combined organic layer 
was washed with water and brine, dried over 
anhydrous Na2SO4 and filtered. The solvent was 
evaporated under vacuum. The crude product was 
purified by silica gel column chromatography with 
CHCl3/CH3OH (100:10) as eluent to afford 3a as a 
pale yellow solid (1.8 g, 93%), mp 212.0-212.8 ºC. 1H 
NMR (600 MHz, CDCl3): δ 8.03 (d, J = 8.0 Hz, 1H), 
7.59 (d, J = 5.0 Hz, 2H), 7.42 (dd, J = 7.7, 8.8 Hz, 
2H), 7.34 (t, J = 7.7 Hz, 1H), 7.07 (s, 1H), 6.77 (d, J = 
8.8 Hz, 1H), 3.56 (s, 2H), 2.69-2.62 (m, 8H), 2.39 (s, 
3H). HRMS (ESI, m/z): Calcd for C20H23BrN3O3S 
([M+H]+) 464.0643, found: 464.0633. Compounds 3b, 
3c, and 3d were prepared with the same procedure 
according to 3a, and the data were listed as below. 3-
((4-Methylpiperazin-1-yl)methyl)-1-(phenylsulfonyl)-
1H-indol-5-ol (3b): White solid (1.5 g, 94%), mp 
211.3-212.8 ºC. 1H NMR (600 MHz, CDCl3): δ 7.86 
(d, J = 7.5 Hz, 2H), 7.67 (d, J = 8.9 Hz, 1H), 7.63 (t, J 
= 7.5 Hz, 2H), 7.61 (br, 1H), 7.55 (t, J = 8.0 Hz, 2H), 
7.08 (d, J = 2.1 Hz, 1H), 6.85 (dd, J = 2.1, 8.9 Hz, 
1H), 4.23 (s, 2H), 3.47 (br, 8H), 2.60 (s, 3H). HRMS 
(ESI, m/z): Calcd for C20H24N3O3S ([M+H]+) 
386.1538, found: 386.1538. 1-((4-
Isopropylphenyl)sulfonyl)-3-((4-methylpiperazin-1-
yl)methyl)-1H-indol-5-ol (3c): White solid (1.6 g, 
94%), mp 211.4-212.8 ºC. 1H NMR (600 MHz, 
CDCl3): δ 7.79 (d, J = 8.8 Hz, 1H), 7.72 (d, J = 8.4 
Hz, 2H), 7.40 (s, 1H), 7.22 (d, J = 8.4 Hz, 2H), 6.96 
(d, J = 2.0 Hz, 1H), 6.78 (dd, J = 2.0, 8.8 Hz, 1H), 
3.51 (s, 2H), 2.88-2.83 (m, 1H), 2.49 (s, 8H), 2.26 (s, 
3H), 1.16 (d, J = 6.9 Hz, 6H). HRMS (ESI, m/z): 
Calcd for C23H30N3O3S ([M+H]+) 428.2008, found: 
428.2043. 1-((4-Fluorophenyl)sulfonyl)-3-((4-
methylpiperazin-1-yl)methyl)-1H-indol-5-ol (3d): Pale 
yellow solid (1.5 g, 88%), mp 210.8-212.8 ºC. 1H 
NMR (600 MHz, CDCl3): δ 7.97 (dd, J = 4.9, 8.8 Hz, 
2H), 7.70 (d, J = 8.8 Hz, 1H), 7.56 (s, 1H), 7.41 (t, J = 
8.8 Hz, 2H), 6.99 (d, J = 2.3 Hz, 1H), 6.81 (dd, J = 
2.3, 8.8 Hz, 1H), 3.51 (s, 2H), 2.39 (s, 8H), 2.28 (s, 
3H). HRMS (ESI, m/z): Calcd for C20H23FN3O3S 
([M+H]+) 404.1444, found: 404.1419. 
(e). tert-Butyl 4-((5-methoxy-1H-indol-3-
yl)methyl)piperazine-1-carboxylate (4): The 
formaldehyde solution (1.60 mL, 30% w/v, 0.02 mol) 
was added to the stirred mixture of tert-butyl 
piperazine-1-carboxylate (1.50 g, 0.015 mol) and 
acetic acid (0.62 g, 0.01 mol) in water (1.6 mL) at 10 
℃. The reaction mixture was stirred at 10 ℃ for 15 
min, it was warmed to RT and stirred for another 2 h. 
After the thick syrup was formed, it was added slowly 
to a stirred solution of 5-methoxy-1H-indole (2.0 g, 
0.013 mol) in methanol (13 mL) at 5 ℃. The reaction 
mixture was warmed to RT and stirred for another 3 h. 
The reaction mixture was poured into ice water, and 
the pH was adjusted to 10-12 with aqueous 5 N NaOH 
solution and extracted with EtOAC. The combined 
organic layers were washed with water, brine, dried 
over anhydrous Na2SO4, and filtered. The solvent was 
evaporated under vacuum. The crude product was 
purified by silica gel column chromatography with 
CH2Cl2/MeOH (100:1 to 10:1) as eluent to afford 4 as 
a white solid (4.1 g, 91%), mp 132.8-134.0 ºC. 1H 
NMR (600 MHz, CDCl3): δ 7.31 (d, J = 8.8 Hz, 1H), 
7.09 (d, J = 2.2 Hz, 1H), 6.86 (dd, J = 2.2, 8.8 Hz, 
1H), 6.83 (s, 1H), 3.83 (s, 3H), 3.54 (s, 2H), 3.29 (t, J 
= 4.5 Hz, 4H), 2.36 (t, J = 4.5 Hz, 4H), 1.42 (s, 9H). 
LC-MS (ESI, m/z): Calcd for C19H27N3O3([M+Na]+) 
368.2, found: 368.0. 
(f). tert-Butyl 4-((1-((2-bromophenyl)sulfonyl)-5-
methoxy-1H-indol-3-yl)methyl)piperazine-1-
carboxylate (5a): To a stirred mixture of finely ground 
KOH solid (0.93 g, 16.6 mmol) and 4 (2.7 g, 7.7 
mmol) in THF (8.0 mL), 2-bromobenzenesulphonyl 
chloride (2.6 g, 10.0 mmol) in THF (5.0 mL) was 
added at 15 ℃. After the reaction mixture was stirred 
  
 
at RT for 3 h, the mixture was poured into ice water 
and the PH was adjusted to 9.5-10 with aqueous 2 N 
KOH solution. The mixture was extracted with 
EtOAC. The combined organic layer was washed with 
water, brine, dried over anhydrous Na2SO4 and 
filtered. The solvent was evaporated under vacuum. 
The crude product was purified by silica gel column 
chromatography with CH2Cl2/MeOH (200:1 to 20:1) 
as eluent to afford 5a as a white solid (3.9g, 89.7%), 
mp 136.9-138.7 ºC. 1H NMR (600 MHz, CDCl3): δ 
8.09 (d, J = 6.4 Hz, 1H), 7.66 (d, J = 7.7 Hz, 2H), 7.54 
(d, J = 9.0 Hz, 1H), 7.46 (t, J = 7.7 Hz, 1H), 7.39 (t, J 
= 7.4 Hz, 1H), 7.20 (s, 1H), 6.85 (dd, J = 2.0, 9.0 Hz, 
1H), 3.82 (s, 3H), 3.66 (s, 2H), 3.44 (s, 4H), 2.45 (s, 
4H), 1.45 (s, 9H). LC-MS (ESI, m/z): Calcd for 
C25H30BrN3O5S ([M+Na]+) 526.2, found: 526.4. 
Compounds 5b, 5c, and 5d were prepared with the 
same procedure according to 5a, and the data were 
listed as below. tert-Butyl 4-((5-methoxy-1-
(phenylsulfonyl)-1H-indol-3-yl)methyl)piperazine-1-
carboxylate (5b): White solid (2.7 g, 90%), mp 59.8-
61.2 ºC. 1H NMR (600 MHz, CDCl3): δ 7.87 (d, J = 
9.0 Hz, 1H), 7.82 (d, J = 7.5 Hz, 2H), 7.49 (t, J = 7.5 
Hz, 1H), 7.39 (t, J = 7.7 Hz, 3H), 7.13 (d, J = 2.4 Hz, 
1H), 6.93 (dd, J = 2.4, 9.0 Hz, 1H), 3.80 (s, 3H), 3.56 
(s, 2H), 3.39 (t, J = 4.3 Hz, 4H), 2.34 (t, J = 4.8 Hz, 
4H), 9.05 (s, 9H); LC-MS (ESI, m/z): Calcd for 
C25H31N3O5S ([M+H]+) 486.2, found: 486.2. tert-Butyl 
4-((1-((4-isopropylphenyl)sulfonyl)-5-methoxy-1H-
indol-3-yl)methyl)piperazine-1-carboxylate (5c): 
White solid (3.9 g, 96%), mp 51.3-51.7 ºC. 1H NMR 
(600 MHz, CDCl3): δ 7.88 (d, J = 9.0 Hz, 1H), 7.74 
(d, J = 12.2 Hz, 2H), 7.41 (s, 1H), 7.25 (t, J = 7.3 Hz, 
2H), 7.13 (d, J = 2.4 Hz, 1H), 6.93 (dd, J = 2.4, 9.0 
Hz, 1H), 3.81 (s, 3H), 3.57 (s, 2H), 3.39 (s, 4H), 2.90 - 
2.85 (m, 1H), 2.36 (s, 4H), 1.45 (s, 9H), 1.18 (d, J = 
7.0 Hz, 6H). LC-MS (ESI, m/z): Calcd for 
C28H37N3O5S ([M+Na]+) 550.2, found: 550.1. tert-
Butyl 4-((1-((4-fluorophenyl)sulfonyl)-5-methoxy-1H-
indol-3-yl)methyl)piperazine-1-carboxylate (5d): 
White solid (3.6 g, 93%), mp 138.0-139.3 ºC. 1H 
NMR (600 MHz, CDCl3): δ 7.84 (dd, J = 5.5, 8.9 Hz, 
3H), 7.38 (s, 1H), 7.14 (d, J = 2.2 Hz, 1H), 7.07 (t, J = 
8.4 Hz, 2H), 6.93 (dd, J = 2.2, 8.9 Hz, 1H), 3.81 (s, 
3H), 3.57 (s, 2H), 3.40 (s, 4H), 2.36 (s, 4H), 1.45 (s, 
9H). LC-MS (ESI, m/z): Calcd for C25H30FN3O5S 
([M+H]+) 504.6, found: 504.6.  
(g). 1-((2-Bromophenyl)sulfonyl)-5-methoxy-3-
(piperazin-1-ylmethyl)-1H-indole (6a): To a solution 
of TFA, 5a (1.0 g, 1.8 mmol) was added at RT under 
stirring, the reaction mixture was stirred at RT for 12 
h. The resulted mixture was poured into water (10 
mL), and then extracted with CH2Cl2 after the pH was 
adjusted to 7-8 with aqueous 5 N KOH solution, The 
combined organic layer was washed with water, brine, 
dried over anhydrous Na2SO4, and filtered. The 
solvent was evaporated under vacuum. The crude 
product was purified by silica gel column 
chromatography with CH2Cl2/CH3OH (100:10) as 
eluent to afford 6a as a pale yellow solid (0.8 g, 96%), 
mp 57.6-58.3 ºC. 1H NMR (600 MHz, CDCl3): δ 8.07 
(d, J = 6.8 Hz, 1H), 7.64 (d, J = 10.0 Hz, 2H), 7.54 (d, 
J = 9.0 Hz, 1H), 7.45 (t, J = 7.5 Hz, 1H), 7.37 (t, J = 
7.6 Hz, 1H), 7.18 (d, J = 2.0 Hz, 1H), 6.85 (dd, J = 
2.0, 8.9 Hz, 1H), 3.81 (s, 3H), 3.63 (s, 2H), 2.98 (s, 
4H), 2.55 (s, 4H). HRMS (ESI, m/z): Calcd for 
C20H22BrN3O3S ([M+H]+) 464.0638, found: 464.0639. 
Compounds 6b, 6c, and 6d were prepared with the 
same procedure according to 6a, and the data were 
listed as below. 5-Methoxy-1-(phenylsulfonyl)-3-
(piperazin-1-ylmethyl)-1H-indole (6b): White solid 
(0.7 g, 91%), mp 49.8-50.2 ºC. 1H NMR (600 MHz, 
CDCl3): δ 7.86 (d, J = 9.0 Hz, 1H), 7.83 (d, J = 7.5 
Hz, 2H), 7.50 (t, J = 7.5 Hz, 1H), 7.40 (dd, J = 3.2, 7.6 
Hz, 3H), 7.14 (d, J = 2.2 Hz, 1H), 6.92 (dd, J = 2.2, 
9.0 Hz, 1H), 3.81 (s, 3H), 3.54 (s, 2H), 2.85 (s, 4H), 
2.39 (s, 4H). HRMS (ESI, m/z): Calcd for 
C20H23N3O3S ([M+H]+) 386.1533, found: 386.1530. 1-
((4-Isopropylphenyl)sulfonyl)-5-methoxy-3-(piperazin-
1-ylmethyl)-1H-indole (6c): Pale yellow solid (0.76 g, 
94%), mp 50.2-51.8 ºC. 1H NMR (600 MHz, CDCl3): 
δ 7.87 (d, J = 9.0 Hz, 1H), 7.75 (d, J = 8.3 Hz, 2H), 
7.42 (s, 1H), 7.23 (d, J = 8.3 Hz, 2H), 7.15 (d, J = 2.1 
Hz, 1H), 6.93 (dd, J = 2.2, 9.0 Hz, 1H), 3.81 (s, 3H), 
3.55 (s, 2H), 3.09 (s, 1H), 2.87 (s, 4H), 2.42 (s, 4H), 
1.16 (d, J = 6.8 Hz, 6H). HRMS (ESI, m/z): Calcd for 
C23H29N3O3S ([M+H]+) 428.2002, found: 428.1999. 1-
((4-Fluorophenyl)sulfonyl)-5-methoxy-3-(piperazin-1-
ylmethyl)-1H-indole (6d): White solid (0.72 g, 94 %), 
mp 56.5-58.3 ºC. 1H NMR (600 MHz, CDCl3): δ 7.85 
(dd, J = 5.1, 8.9 Hz, 3H), 7.38 (s, 1H), 7.10 (d, J = 2.0 
Hz, 1H), 7.08 (d, J = 8.4 Hz, 2H), 6.94 (dd, J = 2.0, 
8.9 Hz, 1H), 3.81 (s, 3H), 3.59 (s, 2H), 3.02 (s, 4H), 
2.56 (s, 4H). HRMS (ESI, m/z): Calcd for 
C20H22FN3O3S ([M+H]+) 404.1432, found: 404.1439. 
(h). 1-[(2-Bromophenyl)sulfonyl]-5-[11C]methoxy-3-
[(4-methyl-1-piperazinyl)methyl]-1H-indole (O-
[11C]2a) and 1-[(2-bromophenyl)sulfonyl]-5-methoxy-
3-[(4-[11C]methyl-1-piperazinyl)methyl]-1H-indole 
(N-[11C]2a), 5-[11C]methoxy-3-((4-methylpiperazin-1-
yl)methyl)-1-(phenylsulfonyl)-1H-indole (O-[11C]2b) 
and 5-methoxy-3-((4-[11C]methylpiperazin-1-
yl)methyl)-1-(phenylsulfonyl)-1H-indole (N-[11C]2b), 
1-((4-isopropylphenyl)sulfonyl)-5-[11C]methoxy-3-((4-
methylpiperazin-1-yl)methyl)-1H-indole (O-[11C]2c) 
and 1-((4-isopropylphenyl)sulfonyl)-5-methoxy-3-((4-
[11C]methylpiperazin-1-yl)methyl)-1H-indole (N-
[11C]2c), 1-((4-fluorophenyl)sulfonyl)-5-
[11C]methoxy-3-((4-methylpiperazin-1-yl)methyl)-1H-
indole (O-[11C]2d) and 1-((4-fluorophenyl)sulfonyl)-
5-methoxy-3-((4-[11C]methylpiperazin-1-yl)methyl)-
1H-indole (N-[11C]2d): [11C]CO2 was produced by the 
14N(p,α)11C nuclear reaction in the small volume (9.5 
cm3) aluminum gas target provided with the Siemens 
RDS-111 Eclipse cyclotron. The target gas consisted 
of 1% oxygen in nitrogen purchased as a specialty gas 
from Praxair, Indianapolis, IN. Typical irradiations 
used for the development were 58 µA beam current 
  
 
and 20 min on target. The production run produced 
approximately 37.0 GBq of [11C]CO2 at EOB. The 
precursor 3a-d or 6a-d (0.1-0.3 mg) was dissolved in 
CH3CN (300 µL). To this solution was added aqueous 
KOH (2 M, 2 µL). The mixture was transferred to a 
small reaction vial. No-carrier-added (high molar 
activity) [11C]CH3OTf that was produced by the gas-
phase production method33 within 12 min from 
[11C]CO2 through [11C]CH4 and [11C]CH3Br with 
AgOTf column was passed into the reaction vial at RT 
until radioactivity reached a maximum (2 min), and 
then the reaction vial was isolated and heated at 80 °C 
for 3 min. The contents of the reaction vial were 
diluted with aqueous NaHCO3 (0.1 M, 1 mL). The 
reaction vial was connected to a 3-mL HPLC injection 
loop. The labeled product mixture solution was 
injected onto the semi-preparative HPLC column for 
purification. The product fraction was collected in a 
recovery vial containing 30 mL water. The diluted 
tracer solution was then passed through a C-18 Light 
Sep-Pak cartridge, and washed with water (3 × 10 
mL). The cartridge was eluted with EtOH (3 × 0.4 
mL) to release the labeled product, followed by saline 
(10-11 mL). The eluted product was then sterile-
filtered through a Millex-FG 0.2 µm membrane into a 
sterile vial. Total radioactivity was assayed and total 
volume (10-11 mL) was noted for tracer dose 
dispensing. The overall synthesis time including 
HPLC-SPE purification and reformulation was ~40 
min from EOB. The decay corrected radiochemical 
yield was 40-50%. Retention times in the analytical 
HPLC system were: tR 3a = 5.23 min, tR 6a = 6.84 
min, tR 2a = 7.44 min, tR O-[11C]2a = 7.51 min, tR N-
[11C]2a = 7.49 min; tR 3b = 4.71 min, tR 6b = 6.21 
min, tR 2b = 6.81 min, tR O-[11C]2b = 6.86 min, tR N-
[11C]2b = 6.88 min; tR 3c = 6.76 min, tR 6c = 8.93 min, 
tR 2c = 9.46 min, tR O-[11C]2c = 9.58 min, tR N-[11C]2c 
= 9.61 min; and tR 3d = 5.03 min, tR 6d = 6.58 min, tR 
2d = 7.12 min, tR O-[11C]2d = 7.19 min, tR N-[11C]2d 
= 7.23 min. Retention times in the preparative HPLC 
system were: tR 3a = 6.54 min, tR 6a = 7.25 min, tR 2a 
= 13.53 min, tR O-[11C]2a = 13.72 min, tR N-[11C]2a = 
13.81 min; tR 3b = 6.32 min, tR 6b = 7.85 min, tR 2b = 
12.01 min, tR O-[11C]2b = 12.27 min, tR N-[11C]2b = 
12.23 min; tR 3c = 6.85 min, tR 6c = 9.59 min, tR 2c = 
17.75 min, tR O-[11C]2c = 17.94 min, tR N-[11C]2c = 
17.99 min; and tR 3d = 5.88 min, tR 6d = 7.24 min, tR 
2d = 11.04 min, tR O-[11C]2d = 11.27 min, tR N-
[11C]2d = 11.25 min.  
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• New carbon-11-labeled 5-HT6R antagonists 
were synthesized. 
• A fully automated multi-purpose [11C]-
radiosynthesis module was built up. 
• A semi-preparative RP HPLC-SPE technique 
was employed in radiosynthesis. 
 
